WASHINGTON D.C. – September 15, 2026 – OmegaQuant Analytics, a leading entity in omega-3 testing and research, has announced a significant milestone in its ongoing commitment to advancing public health. The company has been awarded a National Institutes of Health (NIH) Phase I Small Business Innovation Research (SBIR) grant, a prestigious funding mechanism designed to support innovative research and development. This grant will fuel a groundbreaking investigation into the intricate relationship between fatty acid profiles in blood tissues and the future risk of developing age-related macular degeneration (AMD) and glaucoma, two of the leading causes of irreversible vision loss worldwide.
The research aims to leverage OmegaQuant’s established expertise in measuring key fatty acids, particularly EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), through its widely recognized Omega 3 Index test. This innovative project seeks to determine whether specific patterns of various fatty acids, including omega-3s, omega-6s, saturated, and monounsaturated fats, can serve as early predictive indicators for these debilitating eye conditions. The ultimate goal is to develop a more robust and accessible predictive tool that can identify individuals at higher risk, enabling timely interventions and potentially preventing or delaying significant vision impairment.
The Growing Burden of Age-Related Vision Loss
Age-related macular degeneration (AMD) and glaucoma represent a substantial and escalating public health challenge, particularly in aging populations. According to the Centers for Disease Control (CDC), an estimated 20 million Americans suffer from AMD, while approximately 4 million individuals are affected by glaucoma. The societal and economic impact of these conditions is profound. Projections indicate that by 2050, the annual lost productivity in the United States alone due to these vision impairments could exceed $373 billion. This escalating burden underscores the urgent need for proactive strategies and advanced diagnostic tools.
OmegaQuant’s Role in Fatty Acid Research
OmegaQuant has carved a significant niche in the field of fatty acid analysis. For years, the company has provided reliable and accessible testing kits for both consumers and researchers to quantify the Omega 3 Index. This index, a direct measure of EPA and DHA levels within red blood cells, offers a crucial snapshot of an individual’s long-term omega-3 status. The widespread distribution of these test kits has empowered millions to gain a better understanding of their metabolic health. Furthermore, these kits have become an indispensable tool for researchers, enabling them to swiftly obtain baseline data, monitor changes in fatty acid status, and refine clinical study designs in various areas of fatty acid research.
The development of the Omega 3 Index itself is attributed to the pioneering work of Dr. William S. Harris, the founder of OmegaQuant and the head of the Fatty Acid Research Institute (FARI). Dr. Harris’s extensive research has illuminated the importance of omega-3 fatty acids for overall health, and this new NIH-funded project builds directly upon that foundation.
Unraveling the Predictive Power of Fatty Acid Profiles
While several risk factors for AMD and glaucoma are well-documented – including smoking, hypertension, obesity, high cholesterol, cardiovascular disease, diabetes, poor diet, excessive sun exposure, age, sex, and genetics – their collective predictive value remains limited. This leaves a critical gap in identifying individuals who are most vulnerable, especially before irreversible damage occurs.
"The goal of this study is to develop a better prediction tool for assessing the risk of acquiring these conditions," stated Dr. William S. Harris. "We know that omega-3 fatty acids have shown promise in supporting eye health, but we want to investigate if the entire fatty acid profile within red blood cell tissue can be assembled into a predictive ‘fingerprint’ for early assessment of these vision conditions."
This proposed "fingerprint" would encompass not only omega-3s but also the interplay of omega-6s, saturated fats, and monounsaturated fats. By examining these complex interactions, researchers hope to uncover subtle patterns that may signal an elevated risk years before symptoms become apparent or irreversible vision loss occurs.
A Robust Data Foundation for Machine Learning
The Phase I SBIR grant will facilitate a crucial initial step: harmonizing and analyzing data from several prominent, long-standing prospective cohort studies. These include:
- The Framingham Heart Study (FHS): A cornerstone of cardiovascular research, providing decades of health data on thousands of participants.
- Women’s Health Initiative Memory Study (WHIMS): Focused on cognitive health in women, with valuable data on health outcomes over extended periods.
- Multi-Ethnic Study of Atherosclerosis (MESA): Investigating the prevalence and progression of subclinical cardiovascular disease in diverse populations.
- Boston Puerto Rican Health Study (BPRHS): Examining chronic disease risk factors in the Puerto Rican population in Boston.
Collectively, these esteemed cohorts will contribute data from as many as 19,922 individuals. This extensive dataset includes comprehensive information on AMD and glaucoma outcomes, meticulously collected over an average follow-up period exceeding 10 years.
Given the sheer volume of data and the multitude of factors to correlate, the analysis will employ advanced machine learning protocols. This approach is essential for identifying complex, non-linear relationships between fatty acid patterns and the incidence of eye diseases that might be missed by traditional statistical methods.
The Path Forward: From Proof-of-Concept to Validation
The successful completion of Phase I is envisioned as a proof-of-concept. Should the initial findings demonstrate the viability of fatty acid profiles as predictive markers, the research effort can transition to a Phase II component. This subsequent phase would involve larger prospective studies, further refinement of the predictive model, and rigorous validation in diverse populations.
"Our objective is to determine whether the fatty acid patterns we can measure in a blood sample contain information that could help identify eye disease risk years before serious vision loss occurs," Dr. Harris emphasized. "This could be a paradigm shift in how we approach the prevention and management of age-related vision loss, offering a proactive, personalized approach to eye care."
Broader Implications for Preventative Health
The implications of this research extend beyond the immediate scope of AMD and glaucoma. The successful development of a predictive tool based on blood fatty acid profiles could serve as a blueprint for similar investigations into other chronic diseases. The ability to identify individuals at risk for conditions like cardiovascular disease, neurodegenerative disorders, or certain types of cancer through readily accessible biomarkers could revolutionize preventative healthcare.
The NIH’s investment in OmegaQuant’s project signals a growing recognition of the critical role of nutritional biomarkers in disease prediction and prevention. As personalized medicine continues to gain traction, the capacity to leverage an individual’s unique biochemical makeup to forecast health risks will become increasingly valuable.
The utilization of established cohort studies, combined with cutting-edge analytical techniques like machine learning, represents a robust strategy for tackling complex health challenges. The success of this Phase I grant from OmegaQuant could pave the way for a future where early detection of serious eye conditions is not only possible but routine, offering hope and preserving vision for millions worldwide.
About the Author:
Hank Schultz, Senior Editor at SupplySide Supplement Journal, brings a wealth of experience in industry journalism to his reporting. With a background forged in the competitive landscape of daily newspapers, including a tenure at the Pulitzer Prize-winning Rocky Mountain News, Schultz transitioned to the natural products industry over a decade ago. His approach is characterized by a commitment to timely, comprehensive, and fair reporting, prioritizing the needs of the readership. His journalistic excellence was recognized in 2015 with a Special Award for Journalistic Excellence from the American Herbal Products Association (AHPA). Beyond his professional endeavors, Schultz is an avid outdoorsman and a devoted fan of the Green Bay Packers.
